Q2 2017 13F Holders as of 30 Jun 2017
-
Type / Class
-
Equity / COM
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
36,834,954
-
Shares change
-
+1,784,704
-
Total reported value, excl. options
-
$757,321,487
-
Value change
-
+$33,867,907
-
Number of buys
-
57
-
Number of sells
-
-26
-
Price
-
$20.56
Significant Holders of AIMMUNE THERAPEUTICS INC - COM (AIMT) as of Q2 2017
100 filings reported holding AIMT - AIMMUNE THERAPEUTICS INC - COM as of Q2 2017.
AIMMUNE THERAPEUTICS INC - COM (AIMT) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36,834,954 shares
.
Largest 10 shareholders include Foresite Capital Management II, LLC (3,992,517 shares), FMR LLC (3,016,056 shares), Aisling Capital LLC (2,990,000 shares), BlackRock Inc. (2,613,608 shares), VANGUARD GROUP INC (2,476,836 shares), EAGLE ASSET MANAGEMENT INC (2,270,160 shares), TLP GROUP LLC (2,134,476 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1,900,000 shares), PRICE T ROWE ASSOCIATES INC /MD/ (1,396,399 shares), and Palo Alto Investors, LLC (1,289,719 shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.